Last reviewed · How we verify
Liposomal paclitaxel plus capecitabine — Competitive Intelligence Brief
phase 1
Small molecule
Live · refreshed every 30 min
Target snapshot
Liposomal paclitaxel plus capecitabine (Liposomal paclitaxel plus capecitabine) — Nanjing Sike Pharmaceutical Co., Ltd..
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Liposomal paclitaxel plus capecitabine TARGET | Liposomal paclitaxel plus capecitabine | Nanjing Sike Pharmaceutical Co., Ltd. | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Liposomal paclitaxel plus capecitabine CI watch — RSS
- Liposomal paclitaxel plus capecitabine CI watch — Atom
- Liposomal paclitaxel plus capecitabine CI watch — JSON
- Liposomal paclitaxel plus capecitabine alone — RSS
Cite this brief
Drug Landscape (2026). Liposomal paclitaxel plus capecitabine — Competitive Intelligence Brief. https://druglandscape.com/ci/liposomal-paclitaxel-plus-capecitabine. Accessed 2026-05-17.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab